Stay updated on Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check5 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check12 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check32 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the expected content and navigation. This indicates an access issue or site restriction affecting visibility of the study details.SummaryDifference21%

- Check53 days agoChange DetectedThe page’s revision tag changed from v3.6.5 to v3.6.6, signaling the current version of the page content. This update appears to be an administrative version bump rather than a change to the study data itself.SummaryDifference0.1%

- Check75 days agoChange DetectedA new page revision label v3.6.5 was added, replacing the previous v3.6.4, indicating a minor update to the page metadata.SummaryDifference0.0%

- Check89 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a backend/template update; this does not alter the displayed study details, eligibility criteria, or outcomes.SummaryDifference0.0%

Stay in the know with updates to Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.